anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To enable production of a new antifungal antibiotic substance PF1032 having specific physico-chemical and biological properties with low toxicity and salts thereof by culturing a fungal strain PF1032 of the genus Neosartorya. CONSTITUTION:A fungal strain PF1032 (FERM P-11036) of the genus Neosartorya is cultured in a culture medium containing nutriments utilizable by normal microorganisms under aerobic conditions to stop the culture when the amount of accumulated substance PF1032 in the culture attains the maximum. The objective substance is then extracted from the cultured fungal cells with acetone-water, etc., and the culture solution is further extracted with butanol, etc. The resultant extract can be then purified by chromatography to separate the substance PF1032 having the following specific physico-chemical and biological properties. Color and shape; white powder. Melting point; 156-159 deg.C (decomposition). Distinction of basicity, acidity and neutrality; weak acidic substance, etc. Thereby, the objective substance having specific antifungal activity with lower toxicity than that of conventional antifungal antibiotic substances is obtained and usable as an antifungal agent.
The invention relates to application of rhamnosyl icariside II in muscle repair and regeneration. In particular to application of rhamnosyl icariside II in preparing a medicament or a reagent for treating or preventing muscle diseases, promoting muscle repair or promoting muscle regeneration. The muscle injury is traumatic muscle injury or non-traumatic muscle injury. The non-traumatic muscle injury is selected from the group consisting of myogenic muscular atrophy, disuse muscular atrophy, muscular dystrophy, sarcopenia, muscle pathology, and muscle weakness. The invention proves the effects of the rhamnosyl icariside II on the aspects of promoting proliferation or differentiation of muscle cells, increasing the number of myotubes, promoting formation of the myotubes, increasing the length of the myotubes, increasing the width of the myotubes, promoting differentiation of myoblasts or promoting fusion of the muscle cells and the like for the first time. Widens the application direction of the rhamnosyl icariside II and provides a treatment way for relevant diseases of muscles.
The present invention relates to multivalent immunogenic compositions comprising more than one streptococcus pneumoniae polysaccharide protein conjugate, wherein each of the conjugates comprises a polysaccharide from a streptococcus pneumoniae serotype conjugated to a carrier protein, wherein the streptococcus pneumoniae serotypes are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction that includes an aprotic solvent. In a further embodiment, each of the polysaccharide protein conjugates is formed by a conjugation reaction that includes an aprotic solvent. Also provided is a method for inducing a protective immune response in a human patient comprising administering to the patient the multivalent immunogenic composition of the invention. The multivalent immunogenic compositions are useful for providing protection against streptococcus pneumoniae infection and diseases caused by streptococcus pneumoniae. The compositions of the present invention may also be used as part of a treatment regimen that has provided supplemental protection to patients vaccinated with a multivalent vaccine for the prevention of pneumococcal disease.
The present disclosure relates to a method and an assisting system for assisting a user in real-time for selecting products. The method and system involve receiving information of a set of nutrients associated with a product selected by the user. Thereafter, health data and a health goal associated with the user are received from a user profile database. Information of the set of nutrients is then analyzed based on a health effect of pre-stored nutrients similar to the set of nutrients. Based on the analysis, one of a first expected impact or a second expected impact of the set of nutrients is identified based on the health data. The selected product is then detected as suitable for the user upon identifying the first expected impact of the set of nutrients on the health data of user.
Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
OPTISON (perflutren protein-type A microspheres) injectable suspension is an ultrasound contrast agent for intravenous injection. The vial contains a clear liquid lower layer, a white liquid upper layer, and a headspace filled with perflutren gas. After resuspension, the sterile suspension is homogeneous, opaque, and milky-white.

Perflutren is chemically characterized as 1,1,1,2,2,3,3,3-perflutren with a molecular weight of 188, an empirical formula of C3F8 and it has the following structural formula:

Each mL of OPTISON contains 5-8 ×108 protein-type A microspheres, 10 mg albumin human, 0.22 ± 0.11 mg perflutren; and the following excipients: 0.2 mg N-acetyltryptophan, and 0.12 mg caprylic acid in 0.9% aqueous sodium chloride. The headspace of the vial is filled with perflutren gas. The pH is adjusted to 6.4-7.4. The protein in the microsphere shell makes up approximately 5-7% (w/w) of the total protein in the suspension. The microsphere particle size parameters are listed in Table 2.
The combination of cladribine, cytarabine, and G-CSF (CLAG) has exhibited robust synergistic anti-leukemia activity as an induction therapy (IT) in acute myeloid leukemia (AML). However, the impact of CLAG as a bridging therapy (BT) administered between IT and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with relapsed or refractory (R/R) AML remains uncertain. In this retrospective study, we examined the efficacy of CLAG as a transitional strategy prior to allo-HSCT in R/R AML. We included 234 patients with R/R AML who received the modified busulfan plus cyclophosphamide conditioning regimen for allo-HSCT in our center during the past 6 years, performed a propensity-score matching analysis, partitioned them into four distinct cohorts, and further integrated them into the CLAG group and non-CLAG group based on response to IT and utilization of CLAG. Our cohorts encompassed 12 patients in Cohort A (modified composite complete remission (mCRc) after IT, CLAG), 31 in Cohort B (mCRc after IT, non-CLAG), 35 in Cohort C (non-complete remission (non-CR) after IT, CLAG), and 80 in Cohort D (non-CR after IT, non-CLAG). Intriguingly, among patients with non-CR status, the administration of CLAG correlated with a notably statistically diminished risk of relapse and improved survival at 2-year follow-up (Cohort C vs. Cohort D). Employing CLAG as a BT prior to allo-HSCT demonstrates substantial effectiveness, a relative degree of safety, and manageable toxicity in selected R/R AML cases.
NEW MATERIAL:The compound of formula. USE:An antitumor agent for oral administration. It is free from hygroscopicity and has high storage stability. PREPARATION:Aracytidine-5'-stearyl phosphate is used as a starting raw material and dissolved in water. The aqueous solution is adjusted to preferably 10.3-12pH by adding and mixing NaOH thereto. The conditioned solution is concentrated to dryness under reduced pressure to precipitate the objective compound, which is suspended in 3-5 times volume of ethanol and mixed preferably for 2-6hr. the precipitated crystal is separated and dried at room temperature -100 deg.C to obtain beta-type crystal of the objective compound.
The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
An information processing apparatus includes a first selection unit that selects a second image to be compared with a first image from a plurality of candidate images, a setting unit, an overlap range calculation unit, an evaluation value calculation unit, and a second selection unit. The setting unit sets a plurality of combinations including two or more candidate images from among the plurality of candidate images. The overlap range calculation unit calculates an overlap range between the first image and each of the plurality of combinations. The evaluation value calculation unit calculates an evaluation value of each of the plurality of combinations based on the calculated overlap range. The second selection unit selects at least one combination from the plurality of combinations based on the evaluation value. The first selection unit selects the two or more candidate images included in the selected combination as the second image.
During the process of aging, the quality of bones deteriorates making bones more vulnerable for fractures after minor trauma or from normal daily activities. This poor bone quality together with comorbidities increase healing problems and complications and make fixation more difficult. Moreover, immobilization due to fractures has serious complications especially in the elderly. For all theses, fragility fracture-which is defined by WHO as a fracture that is caused by an injury that would be insufficient to fracture normal bones and is the result of reduced compressive and or torsional strength of bone - these fractures have unique criteria making them a special category with its own concerns. One of these fractures is fragility fracture pelvis (FFP) which is expected to triple between 2005 and 2030. This type of fracture has its huge effect on morbidity and mortality of this vulnerable group of people. Due to its special criteria , a new classification system was developed to classify it known as Rommens classification system. This was followed by many literatures focused on this fracture, its morbidity and mortality, role of surgery, minimal invasive techniques and different augmentation fixation techniques, but they did not reach to a clear algorithm for management and did not clearly identify the role of augmented fixation techniques on different outcomes of this fracture . Fixation augmentation techniques which are defined as surgical techniques aimed at increasing implant stability and used in poor bone quality like in geriatric population. the investigators hypothesis is augmented fixation will improve the functional outcomes of fragility fracture pelvis. These techniques may include percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques.

the investigators will try to answer this question which is "what is the effect of augmented fixation techniques on functional outcomes of fragility fracture pelvis? ''.
BACKGROUND/AIM: Patients diagnosed with advanced metastatic colorectal cancer (CRC) confront a bleak prognosis characterized by low survival rates. Anoikis, the programmed apoptosis resistance exhibited by metastatic cancer cells, is a crucial factor in this scenario.
MATERIALS AND METHODS: We employed bulk flow cytometry and RT-qPCR assays, conducted in vivo experiments with mice and zebrafish, and analyzed patient tissues to examine the effects of the B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi1)-midkine (MDK) axis on the cellular response to anoikis. Bmi1 is pivotal in tumorigenesis. This study elucidated the involvement of Bmi1 in conferring anoikis resistance in CRC and explored its downstream targets associated with metastasis.
RESULTS: Elevated levels of Bmi1 expression correlated with distant metastasis in CRC. Suppression of Bmi1 significantly diminished the metastatic potential of CRC cells. Inhibition of Bmi1 led to an increase in the proportion of apoptotic SW620 cells detached from the matrix. This effect was further enhanced by the addition of irinotecan, a topoisomerase I inhibitor. Furthermore, Bmi1 was found to synergize with MDK in modulating CRC viability, with consistent expression patterns observed in in vivo models and clinical tissue specimens. In summary, Bmi1 acted as a regulator of CRC metastatic capability by conferring anoikis resistance. Additionally, it collaborated with MDK to facilitate invasion and distant metastasis.
CONCLUSION: Targeting Bmi1 may offer a promising adjunctive therapeutic strategy when administering traditional chemotherapy regimens to patients with advanced CRC.
Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
Acute dystonic reactions, the most common type of EPS associated with metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of metoclopramide per day. In cancer, chemotherapy patients receiving 1 to 2 mg/kg per dose, the incidence is 2% in patients over the ages of 30 to 35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine (see WARNINGS). 

Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like facies (see WARNINGS). 

Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance (see WARNINGS). 

Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
The present invention relates to a composition, and method of use, of an octahydrobenzo[f]quinoline-based compound represented by structural formula (I). In this formula, R1 is -OH or -OCH¿3? and R?2¿ is -H, -OH or -OCH¿3?. In addition, R?3¿ is a C1 to C2 saturated or unsaturated, alkyl group. Furthermore, R4 is an aryl group, wherein examples of suitable aryl groups, as defined herein, include phenyl and thienyl groups. The method of this invention relates to the use of the claimed compositions to treat psychotic disorders, to treat Parkinson's disease, or to sedate a mammal by administering an effective amount of a claimed composition.
This study is a 12-month, two-arm, parallel controlled trial. Up to 486 adults with overweight or obesity and type 2 diabetes will be randomized to either 1) intervention or 2) usual care. The intervention arm will participate in a WW program which will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics specific to diabetes. Participants in the usual care arm will receive their normal, usual care from their healthcare providers in addition to a session with a Registered Dietician at baseline. All patients will participate in the collection of patient-reported outcomes at baseline and at 6 and 12 months.
The efficacy of immediate-release lacosamide as adjunctive therapy in patients weighing 50 kg or more with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic (PGTC) seizures was established in a 24-week double-blind, randomized, placebo-controlled, parallel-group, multi-center study (Study 5). The study consisted of a 12-week historical baseline period, a 4-week prospective baseline period, and a 24-week treatment period (which included a 6-week titration period and an 18-week maintenance period). Eligible patients on a stable dose of 1 to 3 antiepileptic drugs experiencing at least 3 documented PGTC seizures during the 16-week combined baseline period were randomized 1:1 to receive lacosamide or placebo. Patients were dosed on a fixed-dose regimen. Dosing was initiated at a dose of 100 mg/day in patients weighing 50 kg or more in 2 divided doses. During the titration period, lacosamide doses were adjusted in 100 mg/day increments at weekly intervals to achieve the target maintenance period dose of 400 mg/day in patients weighing 50 kg or more, which was one of three weight-based dosing arms. The primary efficacy endpoint was the time to second PGTC seizure during the 24-week treatment period (Figure 3). The risk of developing a second PGTC seizure was statistically significantly lower in the lacosamide group than in the placebo group during the 24-week treatment period (hazard ratio=0.548, 95% CI of hazard ratio: 0.381, 0.788, p-value = 0.001), with the corresponding risk reduction being 45.2%.

The key secondary efficacy endpoint was the percentage of patients not experiencing a PGTC seizure during the 24-week treatment period. The adjusted Kaplan-Meier estimates of 24-week freedom from PGTC seizures were 31.3% in lacosamide group and 17.2% in placebo group. The adjusted difference between treatment groups was 14.1% (95% CI: 3.2, 25.1, p-value=0.011). 

Additional pediatric use information is approved for UCB Inc.'s Vimpat (lacosamide) tablets, oral solution, and intravenous solution. However, due to UCB Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Based on the current guidelines, ADT alone or combined with is antiandrogens are considered the appropriate active therapy for the patient population planned for this study. Recent data showed that chemotherapy also benefit patients in this setting. Even though, there is a clear unmet medical need for alternative treatment option in metastatic hormone sensitive prostate cancer (mHSPC). Treatments that can delay disease progression, and are associated with less comorbidities would be of significant clinical benefit in this patient population. The study is designed to assess the efficacy and safety of abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone without castration side effects and the other arm a combination of ADT and abiraterone; this last arm is to reflect an Abiraterone ongoing pivotal trial (LATITUDE), that assess the efficacy of adding abiraterone to castration in this setting of patients. Abiraterone had already showed clinical benefit in CRPC patients without prior chemotherapy.
The peritoneum is inflated with carbon dioxide (insufflation) and head-down position is performed (Trendelenburg) during laparoscopic colon and gynecologic surgeries. Intracranial pressure (ICP) may be affected by positive intraabdominal pressure due to pneumoperitoneum. The Trendelenburg position (usually at a degree of 25-400) causes increasing in the pressure of cerebrospinal fluid during surgery. Therefore, cerebral edema and an increasing in ICP may occur. It is difficult to measure the several levels of intracranial pressure during abdominal surgery, and direct monitoring with intracranial devices is often impossible. Measurement of optic nerve sheath diameter (ONSD) via ultrasonography has been developed as an alternative method for evaluating intracranial pressure. The optic nerve is an extension of the central nervous system, surrounded by cerebrospinal fluid (CSF) and continues with the nerve sheath. Increased intracranial pressure may cause in expanding of the optic nerve sheath and may increase the diameter. Therefore, measuring the diameter of the optic nerve sheath via ultrasonography is considered as a non-invasive, easy-to-apply and reliable method to evaluate intracranial pressure.

In this study, we aimed to evaluate the changes of optic nerve sheath diameter in patients who will undergo laparoscopic colon and gynecologic surgery during trendelenburg position. Our primary goal is to compare the optic nerve sheath diameters via ultrasonography, and our secondary aim is to evaluate the effect of this change on intracranial pressure.
Only administer AFREZZA via oral inhalation using the AFREZZA Inhaler. Administer AFREZZA at the beginning of each meal. Administer AFREZZA using a single inhalation per cartridge (if the dose is greater than the contents of a single cartridge, more than one cartridge is needed) [see Dosage and Administration (2.3)]. For additional administration instructions on how to use the AFREZZA Inhaler [see Dosage and Administration (2.6)] and see the Instructions for Use.

The AFREZZA Inhaler can be used for up to 15 days from the date of first use. After 15 days of use, the inhaler must be discarded and replaced with a new inhaler.
<P>PROBLEM TO BE SOLVED: To provide supplements each containing a Japanese parsley extract, having cell-activating effect and cosmetic effects including skin beautifying effect.  <P>SOLUTION: The one supplement contains a Japanese parsley extract which contains a polar solvent-soluble fraction in the water-insoluble fraction of Oenanthe javanica (Bl.) DC. The other supplement contains a Japanese parsley extract which contains a polar solvent-soluble fraction in the water-insoluble fraction of Oenanthe javanica (Bl.) DC. and a acetone-insoluble fraction in the hot water extracted fraction of Oenanthe javanica (Bl.) DC.  <P>COPYRIGHT: (C)2004,JPO
Despite a standardized diagnostic examination, cancer of unknown primary (CUP) is a rare metastatic malignancy with an unidentified tissue of origin (TOO). Patients diagnosed with CUP are typically treated with empiric chemotherapy, although their prognosis is worse than those with metastatic cancer of a known origin. TOO identification of CUP has been employed in precision medicine, and subsequent site-specific therapy is clinically helpful. For example, molecular profiling, including genomic profiling, gene expression profiling, epigenetics and proteins, has facilitated TOO identification. Moreover, machine learning has improved identification accuracy, and non-invasive methods, such as liquid biopsy and image omics, are gaining momentum. However, the heterogeneity in prediction accuracy, sample requirements and technical fundamentals among the various techniques is noteworthy. Accordingly, we systematically reviewed the development and limitations of novel TOO identification methods, compared their pros and cons and assessed their potential clinical usefulness. Our study may help patients shift from empirical to customized care and improve their prognoses.